The National Center for Interventional Biophotonic Technologies (NCIBT)

国家介入生物光子技术中心 (NCIBT)

基本信息

  • 批准号:
    10744968
  • 负责人:
  • 金额:
    $ 6.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-20 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY – Overall The long-term goal of the National Center for Interventional Biophotonic Technologies (NCIBT) is to promote public health by advancing a new paradigm for intraprocedural, image-guided decision making. The Center's strategy is to advance optical spectroscopy and imaging technologies, to develop means of providing imaging results to medical practitioners at the time, in the form, and within the context they will be most useful in guiding decisions, and to maximize the impact of this work by involving as many scientists and physicians as possible in developing and using these technologies. Initially, the Center will promote technological advancements of interventional fluorescence lifetime imaging (iFLIM) and interferometric diffuse optical spectroscopy (iDOS) and their translation into clinical use. An open-ended intraprocedural platform will incorporate them and, eventually, complementary optical imaging technologies. Specifically, NCIBT will (1) advance scalable optical imaging technology, built from the perspective of intelligent optical system design, to characterize tissue properties in the most effective manner; (2) develop an intraprocedural platform that physically incorporates these technologies and integrates the resulting imaging data, details of the procedure, and patient-specific information within AI- based decision algorithms that guide, in real-time, therapeutic decisions, and (3) disseminate these technological advancements to research institutions and medical centers. The significance of this project derives from its potential for rapid advancement, catalyzed by an AI-directed holistic approach to instrument design, of its optical imaging technologies and platform and their relevance to managing humanity's most common afflictions - cancer, stroke, heart disease, trauma, infection, and degenerative diseases. NCIBT will ensure the national impact of these technological advancements by creating and expanding a network of collaborative research and service projects broadly distributed nationwide and implementing a comprehensive training and dissemination program. Annual workshops, hand-on training sessions at national meetings, in special courses and at UC Davis, presentations and publications will educate, train, equip and diversify potential users of NCIBT technology. Bridging gaps between engineering and medicine and between technology development and clinical application will ensure that the needed technologies are developed and applied clinically to improve the nation's health.
项目概述-整体

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Virtual tissue staining in pathology using machine learning
使用机器学习进行病理学虚拟组织染色
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Griffith R. Harsh其他文献

First In-Human Intraoperative Near-Infrared Fluorescence Imaging of Glioblastoma Using Cetuximab-IRDye800: Results from a Pilot Study
  • DOI:
    10.1016/j.jamcollsurg.2017.07.315
  • 发表时间:
    2017-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah E. Miller;Willemieke S. Tummers;Nutte (Tarn) Teraphongphom;Alifia J. Hasan;Robert D. Ertsey;Griffith R. Harsh;Edward D. Plowey;Gerald A. Grant;Gordon H. Li;Eben L. Rosenthal
  • 通讯作者:
    Eben L. Rosenthal
Differential regulation of platelet-derived growth factor A and B chain messages in microvascular endothelial cells
  • DOI:
    10.1016/s0022-2828(87)80651-x
  • 发表时间:
    1987-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Niel F. Starksen;Griffith R. Harsh;Verna C. Gibbs;Lewis T. Williams
  • 通讯作者:
    Lewis T. Williams
Neurosurgical Resident Error: A Survey of U.S. Neurosurgery Residency Training Program Directors' Perceptions
  • DOI:
    10.1016/j.wneu.2017.10.022
  • 发表时间:
    2018-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Raghav Gupta;Justin M. Moore;Nimer Adeeb;Christoph J. Griessenauer;Anna M. Schneider;Chirag D. Gandhi;Griffith R. Harsh;Ajith J. Thomas;Christopher S. Ogilvy
  • 通讯作者:
    Christopher S. Ogilvy
Haploinsufficiency of emNFKBIA/em reshapes the epigenome antipodal to the emIDH/em mutation and imparts disease fate in diffuse gliomas
emNFKBIA/em 的单倍体不足重塑了与 emIDH/em 突变相对的表观基因组,并赋予弥漫性胶质瘤疾病命运
  • DOI:
    10.1016/j.xcrm.2023.101082
  • 发表时间:
    2023-06-20
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Markus Bredel;Lluís Espinosa;Hyunsoo Kim;Denise M. Scholtens;Joseph P. McElroy;Rajani Rajbhandari;Wei Meng;Thomas M. Kollmeyer;Tathiane M. Malta;Michael A. Quezada;Griffith R. Harsh;Teresa Lobo-Jarne;Laura Solé;Aran Merati;Surya Nagaraja;Sindhu Nair;Jaclyn J. White;Nanda K. Thudi;Jessica L. Fleming;Amy Webb;Arnab Chakravarti
  • 通讯作者:
    Arnab Chakravarti
A multi-institutional experience with stereotactic radiosurgery for solitary brain metastases
  • DOI:
    10.1016/0360-3016(93)90714-7
  • 发表时间:
    1993-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    John C. Flickinger;Douglas Kondziolka;L. Dade Lunsford;Robert J. Coffey;Michael L. Goodman;Edward G. Shaw;W. Robert Hudgins;Richard Weiner;Griffith R. Harsh;Penny K. Sneed;David A. Larson
  • 通讯作者:
    David A. Larson

Griffith R. Harsh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Griffith R. Harsh', 18)}}的其他基金

Technology Training and Dissemination
技术培训与传播
  • 批准号:
    10649488
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
UC Davis Clinician Neuroscientist Development Program
加州大学戴维斯分校临床医生神经科学家发展计划
  • 批准号:
    10334321
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
UC Davis Clinician Neuroscientist Development Program
加州大学戴维斯分校临床医生神经科学家发展计划
  • 批准号:
    10672886
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
Technology Training and Dissemination
技术培训与传播
  • 批准号:
    10424950
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
The National Center for Interventional Biophotonic Technologies (NCIBT)
国家介入生物光子技术中心 (NCIBT)
  • 批准号:
    10649445
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
The National Center for Interventional Biophotonic Technologies (NCIBT)
国家介入生物光子技术中心 (NCIBT)
  • 批准号:
    10424945
  • 财政年份:
    2022
  • 资助金额:
    $ 6.74万
  • 项目类别:
Stanford Neurosurgery Resident Research Education Program
斯坦福大学神经外科住院医师研究教育计划
  • 批准号:
    8628240
  • 财政年份:
    2009
  • 资助金额:
    $ 6.74万
  • 项目类别:
Stanford Neurosurgery Resident Research Education Program
斯坦福大学神经外科住院医师研究教育计划
  • 批准号:
    8234656
  • 财政年份:
    2009
  • 资助金额:
    $ 6.74万
  • 项目类别:
Stanford Neurosurgery Resident Research Education Program
斯坦福大学神经外科住院医师研究教育计划
  • 批准号:
    8230757
  • 财政年份:
    2009
  • 资助金额:
    $ 6.74万
  • 项目类别:
Stanford Neurosurgery Resident Research Education Program
斯坦福大学神经外科住院医师研究教育计划
  • 批准号:
    8435675
  • 财政年份:
    2009
  • 资助金额:
    $ 6.74万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 6.74万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了